Frank Dolan

Urgent Call to Action: U.S. Risks Losing Biotech Dominance to China Without $15 Billion Investment

Urgent Call to Action: U.S. Risks Losing Biotech Dominance to China Without $15 Billion Investment

Frank Dolan April 9, 2025

ABL Bio Joins Forces with GSK: Revolutionizing Neurodegenerative Disease Treatments with Major Pharma Collaborations

ABL Bio Joins Forces with GSK: Revolutionizing Neurodegenerative Disease Treatments with Major Pharma Collaborations

Frank Dolan April 9, 2025

Navigating Stock Market Volatility: How Trump's Tariffs Impact the Health Tech Industry's Future

Navigating Stock Market Volatility: How Trump’s Tariffs Impact the Health Tech Industry’s Future

Frank Dolan April 8, 2025

Tango Therapeutics Slashes Workforce by 20% to Focus on Promising Cancer Treatments Amid Biotech Market Challenges

Tango Therapeutics Slashes Workforce by 20% to Focus on Promising Cancer Treatments Amid Biotech Market Challenges

Frank Dolan April 8, 2025

Biotech Market Blues: How Trump’s Tariff Proposals and FDA Firings are Shaking Investor Confidence

Biotech Market Blues: How Trump’s Tariff Proposals and FDA Firings are Shaking Investor Confidence

Frank Dolan April 7, 2025

How Trump's Tariff Policy Threatens Healthcare Supplies and Patient Care: Industry Insights and Impacts

How Trump’s Tariff Policy Threatens Healthcare Supplies and Patient Care: Industry Insights and Impacts

Frank Dolan April 7, 2025

Revolutionizing Diabetes and Obesity Treatment: Jens Juul Holst and the Breakthrough Prize for GLP-1 Discoveries

Revolutionizing Diabetes and Obesity Treatment: Jens Juul Holst and the Breakthrough Prize for GLP-1 Discoveries

Frank Dolan April 6, 2025

Major Staff Cuts at FDA and HHS: What it Means for Drug Approvals and Biopharma R&D

Major Staff Cuts at FDA and HHS: What it Means for Drug Approvals and Biopharma R&D

Frank Dolan April 5, 2025

FTC's Bold Move: Reinvigorating the Fight Against Pharmacy Benefit Managers for Fair Drug Pricing

FTC’s Bold Move: Reinvigorating the Fight Against Pharmacy Benefit Managers for Fair Drug Pricing

Frank Dolan April 4, 2025

2025 M&A Landscape: Pharma Giants Hold Back on Billion-Dollar Acquisitions Amid Political Uncertainty

2025 M&A Landscape: Pharma Giants Hold Back on Billion-Dollar Acquisitions Amid Political Uncertainty

Frank Dolan April 4, 2025

F-star Therapeutics Goes Private: What This Surprising Shift Means for the Biotech Landscape

F-star Therapeutics Goes Private: What This Surprising Shift Means for the Biotech Landscape

Frank Dolan April 4, 2025

Collective Health Partners with Providence Health Plan: A New Era of Collaboration in Oregon's Health Insurance Landscape

Collective Health Partners with Providence Health Plan: A New Era of Collaboration in Oregon’s Health Insurance Landscape

Frank Dolan April 3, 2025

2025 Biotech Investment Trends: The Rise of Megarounds and What it Means for Startups

2025 Biotech Investment Trends: The Rise of Megarounds and What it Means for Startups

Frank Dolan April 3, 2025

Neurona Therapeutics Raises $102 Million to Pioneer Cell Therapy for Epilepsy

Neurona Therapeutics Raises $102 Million to Pioneer Cell Therapy for Epilepsy

Frank Dolan April 3, 2025

FTC Pauses Legal Action Against Pharmacy Benefit Managers: What This Means for Drug Pricing and Patient Access

FTC Pauses Legal Action Against Pharmacy Benefit Managers: What This Means for Drug Pricing and Patient Access

Frank Dolan April 2, 2025

Mass Layoffs at HHS: Understanding the Impact of Trump Administration's Workforce Cuts on Public Health

Mass Layoffs at HHS: Understanding the Impact of Trump Administration’s Workforce Cuts on Public Health

Frank Dolan April 2, 2025

Vida Ventures Bolsters Leadership with New Managing Directors Ahead of Fourth Fund Launch

Vida Ventures Bolsters Leadership with New Managing Directors Ahead of Fourth Fund Launch

Frank Dolan April 2, 2025

EMA Proposes Game-Changing Regulatory Reforms to Accelerate Biosimilars Approval and Cut Costs

EMA Proposes Game-Changing Regulatory Reforms to Accelerate Biosimilars Approval and Cut Costs

Frank Dolan April 1, 2025

Airna Secures $155 Million Series B Funding to Revolutionize Treatment for Alpha-1 Antitrypsin Deficiency with RNA Editing

Airna Secures $155 Million Series B Funding to Revolutionize Treatment for Alpha-1 Antitrypsin Deficiency with RNA Editing

Frank Dolan April 1, 2025

Texas Judge Dismisses Johnson & Johnson's Talc Bankruptcy Plan: What It Means for Ongoing Lawsuits

Texas Judge Dismisses Johnson & Johnson’s Talc Bankruptcy Plan: What It Means for Ongoing Lawsuits

Frank Dolan April 1, 2025

Stay up to date on the latest news

By pressing the Subscribe button, you confirm that you have read our Privacy Policy.

Insilico Medicine's Third Attempt at an IPO: Aiming Big in Hong Kong's Booming Biotech Market

Insilico Medicine’s Third Attempt at an IPO: Aiming Big in Hong Kong’s Booming Biotech Market

Biotech Sector Faces Major Workforce Cuts: Layoffs Surge as Firms Navigate Market Turbulence

Biotech Sector Faces Major Workforce Cuts: Layoffs Surge as Firms Navigate Market Turbulence

Insitro Cuts Workforce by 22% Amidst Biotech Industry Challenges: What It Means for the Future of AI in Medicine

Insitro Cuts Workforce by 22% Amidst Biotech Industry Challenges: What It Means for the Future of AI in Medicine

Email Us

info at arsenal-advisors.com

Headquarters

Cambridge, MA USA